Inclisiran
Inclisiran. GalNAc-conjugated small interfering RNA. GalNAc moiety targets asialoglycoprotein receptor on hepatocytes → selective hepatic uptake. siRNA silences PCSK9…
GalNAc-conjugated small interfering RNA. GalNAc moiety targets asialoglycoprotein receptor on hepatocytes → selective hepatic uptake. siRNA silences PCSK9 mRNA → preserves hepatic LDLR → 50% LDL reduction. Twice-yearly dosing — extraordinary convenience vs mAb PCSK9 inhibitors (every 2–4 weeks).
Related compounds
- Alirocumab — synergistic
Sources: PMID:32187462, PMID:37164838, PMID:31630870